learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 702 resultsresearch Characterization of an In Vivo Model for the Study of Eyelash Biology and Trichomegaly: Mouse Eyelash Morphology, Development, Growth Cycle, and Anagen Prolongation by Bimatoprost
The study showed that mouse eyelashes can be used to study eyelash growth and that bimatoprost makes them longer and more numerous.
research Fine Structure and Immunocytochemistry of Monotreme Hairs, with Emphasis on the Inner Root Sheath and Trichohyalin-Based Cornification During Hair Evolution
Monotreme hair structure and protein distribution are similar to other mammals, but their inner root sheath cornifies differently, suggesting a unique evolution from reptile skin.
research Osteopontin Gene Is Expressed in the Dermal Papilla of Pelage Follicles in a Hair-Cycle-Dependent Manner
The osteopontin gene is active in a specific part of rat hair follicles during a certain hair growth phase and might affect hair cycle and diseases.
research NF-κB Participates in Mouse Hair Cycle Control and Plays Distinct Roles in Various Pelage Hair Follicle Types
NF-κB is crucial for different stages and types of hair growth in mice.
research Hair Morphogenesis In Vitro: Formation of Hair Structures Suitable for Implantation
Scientists created early-stage hairs from mouse cells that grew into normal, pigmented hair when implanted into other mice.
Community Join
5 / 106 resultscommunity Pelage Announces Positive Results of Phase 2a Trials for PP405
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Pelage, PP405, is creating a database for potential new trial volunteers
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
community Guys… Pelage might just be the one. They might actually find the cure. I work in tech - let me explain.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
community I think we should all keep an eye out for Pelage PP405. February 2025 will be interesting.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.